Nintedanib
– a triple angiokinase inhibitor
•
Oral triple angiokinase inhibitor targeting:
1,2
and
RET
and
Flt-3
•
No drug–drug interaction liability via CYP450
3
•
Manageable safety profile in combination
with:
–
Docetaxel
3
–
Pemetrexed
4
–
Paclitaxel/carboplatin
5
–
Gemcitabine/cisplatin
6
1. Hilberg F, et al. Cancer Res 2008;68:4774–8; 2. Boehringer Ingelheim Data on file;
3. Stopfer P, et al.
Xenobiotica
. 2011;41:297–311;
4. Bousquet G, et al. Br
J Cancer 2011;105:1640–5; 5. Ellis PM, et al. Clin Cancer Res 2010;16:2881–9; 6. Doebele RC, et al. Ann Oncol 2012;23:2094–102.
IC
50
(nmol/L)
VEGFR
1 / 2 / 3
34/ 21/ 13
PDGFR
α / β
59/ 65
FGFR
1 / 2 / 3
69/ 37/ 108
By targeting the 3 major angiogenesis signaling pathways Nintedanib
prevents
further tumor
growth
and
related tumor escape mechanisms
